Such a massive subscription reflects investor confidence in Anthem’s business model and financial strength.Anthem Biosciences IPO GMP.
Listing Day Performance: A Strong Debut
Anthem Biosciences made a stellar entry on the stock exchanges:
| Exchange | Listing Price | Gain Over Issue Price |
|---|---|---|
| NSE | ₹723.05 | +26.85% |
| BSE | ₹723.10 | +26.86% |
Although the actual listing was slightly below GMP expectations, a 27% gain still qualifies as a strong debut.
GMP vs Actual Listing: A Small Gap
While the GMP indicated a potential listing around ₹740, the stock opened at ₹723. This slight dip can be attributed to broader market volatility and investor profit booking.
Yet, the 27% gain over the issue price validates the IPO’s strength.
Advertisement
Financial Highlights Before IPO
Anthem Biosciences showcased solid financials before going public:
- Revenue (FY25): ₹1,844 crore
- EBITDA Margin: 37%
- Return on Capital Employed (ROCE): 27%
- No Debt Pressure: Strong balance sheet
These fundamentals further justified the rich valuation and high GMP.
